Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
2(20%)
Results Posted
0%(0 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_4
3
30%
Ph phase_3
5
50%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 3Large-scale testing
5(50.0%)
Phase 4Post-market surveillance
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Active, not recruiting2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 35 (50.0%)
Phase 43 (30.0%)

Trials by Status

unknown110%
completed550%
active_not_recruiting220%
terminated220%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruitingphase_3

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NCT04513717
active_not_recruitingphase_3

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
terminatedphase_3

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

NCT00651326
completedphase_1

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

NCT00054106
completedphase_3

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

NCT00003653
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04513717Phase 3

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Active Not Recruiting
NCT05050084Phase 3

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Active Not Recruiting
NCT00651326Phase 3

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Terminated
NCT00054106Phase 1

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Completed
NCT00003653Phase 3

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Completed
NCT00002633Phase 3

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed
NCT01816789Phase 4

Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles

Terminated
NCT01213147Phase 4

Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders

Completed
NCT00823121Phase 1

Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification

Unknown
NCT00830492Phase 4

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10